寻找指导孤独症谱系障碍干预的生物标志物:一项系统综述
该系统综述检索了MEDLINE、Embase和Scopus,纳入280篇文献,涉及940种生物标志物,其中755种仅见于单篇报道。多数研究样本量中位数为64,仅能识别大效应量标志物,且重复性差。结论是目前尚无足够证据可用于指导孤独症谱系障碍临床试验的反应生物标志物。
要点
- 目前无反应生物标志物有足够证据指导孤独症谱系障碍临床试验。
- 多数研究样本量小,仅能识别大效应量标志物,且重复性差。
- 需统一实验设计、多重比较校正、正式重复、数据共享和预注册。
核心结论
- 目前尚无反应生物标志物具备足够证据可用于指导孤独症谱系障碍临床试验。
研究设计与样本
- 系统综述检索MEDLINE、Embase和Scopus(2020年4月),纳入评估生物标志物与孤独症谱系障碍症状相关性的干预性或人体研究。
主要发现
- 共检索到5799条独立记录,最终纳入280篇文章,报告940种生物标志物,其中755种仅见于单篇发表。
- 分子生物标志物检测最多,包括细胞因子、生长因子、氧化应激指标、神经递质和激素,其次是神经生理(如EEG和眼动追踪)、神经影像(如功能MRI)和其他生理指标。
- 研究在表型、人口学特征、检测组织和生物标志物检测方法上高度异质。
- 纳入研究的总样本量中位数为64,几乎所有研究仅能识别大效应量的生物标志物。
- 个体水平值和汇总统计的报告不一致,妨碍了汇总分析和meta分析;多种生物标志物在多项研究中结果多不一致,呈现「重复危机」。
临床怎么用
- 当前不宜将现有反应生物标志物用于指导孤独症谱系障碍临床试验或临床干预决策。
局限性
- 纳入研究异质性高、样本量小、报告不一致且重复性差,限制了证据合成与结论推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to catalog and evaluate response biomarkers correlated with autism spectrum disorder (ASD) symptoms to improve clinical trials. METHODS: A systematic review of MEDLINE, Embase, and Scopus was conducted in April 2020. Seven criteria were applied to focus on original research that includes quantifiable response biomarkers measured alongside ASD symptoms. Interventional studies or human studies that assessed the correlation between biomarkers and ASD-related behavioral measures were included. RESULTS: A total of 5,799 independent records yielded 280 articles for review that reported on 940 biomarkers, 755 of which were unique to a single publication. Molecular biomarkers were the most frequently assayed, including cytokines, growth factors, measures of oxidative stress, neurotransmitters, and hormones, followed by neurophysiology (e.g., EEG and eye tracking), neuroimaging (e.g., functional MRI), and other physiological measures. Studies were highly heterogeneous, including in phenotypes, demographic characteristics, tissues assayed, and methods for biomarker detection. With a median total sample size of 64, almost all of the reviewed studies were only powered to identify biomarkers with large effect sizes. Reporting of individual-level values and summary statistics was inconsistent, hampering mega- and meta-analysis. Biomarkers assayed in multiple studies yielded mostly inconsistent results, revealing a "replication crisis." CONCLUSIONS: There is currently no response biomarker with sufficient evidence to inform ASD clinical trials. This review highlights methodological imperatives for ASD biomarker research necessary to make definitive progress: consistent experimental design, correction for multiple comparisons, formal replication, sharing of sample-level data, and preregistration of study designs. Systematic "big data" analyses of multiple potential biomarkers could accelerate discovery.
引用
- Parellada M, Andreu-Bernabeu Á, Burdeus M, et al. In Search of Biomarkers to Guide Interventions in Autism Spectrum Disorder: A Systematic Review. Am J Psychiatry. 2022. PMID: 36475375. doi:10.1176/appi.ajp.21100992
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。